Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma.

Korn S, Schumann C, Kropf C, Stoiber K, Thielen A, Taube C, Buhl R.

Ann Allergy Asthma Immunol. 2010 Oct;105(4):313-9. doi: 10.1016/j.anai.2010.07.007.

PMID:
20934632
2.
3.

Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.

Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R.

Respir Med. 2009 Nov;103(11):1725-31. doi: 10.1016/j.rmed.2009.05.002. Epub 2009 Jun 9.

4.

Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.

Massanari M, Kianifard F, Zeldin RK, Geba GP.

Allergy Asthma Proc. 2009 Sep-Oct;30(5):534-9. doi: 10.2500/aap.2009.30.3245. Epub 2009 May 22.

PMID:
19467177
5.

Omalizumab in the treatment of severe asthma: efficacy and current problems.

Pelaia G, Renda T, Romeo P, Busceti MT, Maselli R.

Ther Adv Respir Dis. 2008 Dec;2(6):409-21. doi: 10.1177/1753465808100431. Review.

PMID:
19124386
6.

Omalizumab in patients with severe asthma: the XCLUSIVE study.

Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, Thielen A, Rottbauer W, Kroegel C.

Clin Respir J. 2012 Oct;6(4):215-27. doi: 10.1111/j.1752-699X.2011.00263.x. Epub 2011 Aug 9.

PMID:
21740532
7.

Omalizumab as add-on therapy to inhaled steroids for asthma.

Hadj Tahar A.

Issues Emerg Health Technol. 2004 Jun;(58):1-4.

PMID:
15455487
8.

One year treatment with omalizumab is effective and well tolerated in Japanese Patients with moderate-to-severe persistent asthma.

Ohta K, Yamamoto M, Sato N, Ikeda K, Miyamoto T.

Allergol Int. 2010 Jun;59(2):167-74. doi: 10.2332/allergolint.09-OA-0137. Epub 2010 Feb 25.

9.

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K.

Allergy. 2004 Jul;59(7):709-17.

10.

Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.

Shimizu Y, Dobashi K, Fueki N, Fueki M, Okada T, Tomioka S, Makino S, Mori M.

J Biol Regul Homeost Agents. 2011 Apr-Jun;25(2):177-86.

PMID:
21880206
11.

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.

Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ.

J Allergy Clin Immunol. 2009 Jan;123(1):107-113.e3. doi: 10.1016/j.jaci.2008.09.050.

PMID:
19130931
12.

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N.

J Allergy Clin Immunol. 2001 Aug;108(2):184-90.

PMID:
11496232
13.

Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients.

Domingo C, Moreno A, José Amengual M, Montón C, Suárez D, Pomares X.

Curr Med Res Opin. 2011 Jan;27(1):45-53. doi: 10.1185/03007995.2010.536208. Epub 2010 Nov 18.

PMID:
21083517
14.

Use of omalizumab in a severe asthma clinic.

Gibson PG, Taramarcaz P, McDonald VM.

Respirology. 2007 Nov;12 Suppl 3:S35-44; discussion S45-7.

PMID:
17956518
15.
16.

Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.

Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G.

Respir Med. 2008 Oct;102(10):1371-8. doi: 10.1016/j.rmed.2008.06.002. Epub 2008 Jul 26.

17.

Spotlight on omalizumab in allergic asthma.

Bang LM, Plosker GL.

BioDrugs. 2004;18(6):415-8. Review.

PMID:
15571425
18.

Therapeutic efficacy of omalizumab.

MacGlashan D Jr.

J Allergy Clin Immunol. 2009 Jan;123(1):114-5. doi: 10.1016/j.jaci.2008.10.053. No abstract available.

PMID:
19130932
19.

Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.

Limb SL, Starke PR, Lee CE, Chowdhury BA.

J Allergy Clin Immunol. 2007 Dec;120(6):1378-81. Epub 2007 Oct 22. Review. Erratum in: J Allergy Clin Immunol. 2008 Jan;121(1):178.

PMID:
17936893
20.

Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.

Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J.

Curr Med Res Opin. 2001;17(4):233-40.

PMID:
11922396
Items per page

Supplemental Content

Write to the Help Desk